Cellipont Bioservices announced it has entered into a collaboration with Ernexa Therapeutics (ERNA). The partnership agreement will focus on Engineering, Differentiation, and Production activities to advance ERNA-101, Ernexa’s lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERNA: